25 Staniford St Erich Lindemann Mtl Hlth Ctr
Boston MA 02114
Medical School: Other - 1991
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 225438
Request Appointment Information
Awards & Recognitions
Dr. Xiaoduo Fan is associated with these group practices
|HCPCS Code||Description||Average Price||Average Price
Allowed By Medicare
|HCPCS Code:G0179||Description:MD recertification HHA PT||Average Price:$95.00||Average Price Allowed
|HCPCS Code:90801||Description:Psy dx interview||Average Price:$201.32||Average Price Allowed
|HCPCS Code:G0180||Description:MD certification HHA patient||Average Price:$95.00||Average Price Allowed
|HCPCS Code:90862||Description:Medication management||Average Price:$80.65||Average Price Allowed
HCPCS Code Definitions
- Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per certification period
- Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per re-certification period
Medical Malpractice Cases
Medical Board Sanctions
Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. - Behavioural brain research
Growing evidence suggests abnormalities in brain morphology including hippocampal structure in patients with methamphetamine (MA) dependence. This study was performed to examine hippocampal volume in abstinent MA users, and to further explore its relationship with cognitive function. 30 abstinent MA users (20 males and 10 females) with average 5.52 months of duration of abstinence and 29 healthy controls (19 males and 10 females) age 18-45 years old were recruited for clinical assessment and imaging scan. FreeSurfer was used to segment the hippocampus bilaterally, and hippocampal volumes were extracted for group and gender comparisons. Cognitive function was measured using the CogState Battery Chinese language version (CSB-C). Analysis of covariance (ANCOVA) controlling for education showed a significant group by gender interaction for the right hippocampal relative volume adjusted for total brain size (p=0.020); there was a significant difference between male controls and female controls (p<0.001), but such a difference did not exist between male patients and female patients (p=0.203). No significant correlations were found between hippocampal volume and cognitive measures. There seems to be a gender difference in how MA affects hippocampal volume in abstinent MA users. Hippocampus might be an important treatment target for cognitive improvement and functional recovery in this patient population, especially in females.Copyright Â© 2015 Elsevier B.V. All rights reserved.
Neural correlates of the preserved inhibition of return in schizophrenia. - PloS one
Inhibition of return (IOR) is an attentional mechanism that previously has been reported to be either intact or blunted in subjects with schizophrenia (SCZ). In the present study, we explored the neural mechanism of IOR in SCZ by comparing the target-locked N1 and P1 activity evoked by valid-cued trials with that evoked by invalid-cued trials. Twenty-seven schizophrenia patients and nineteen healthy controls participated in a task involving covert orienting of attention with two stimulus onset asynchronies (SOAs: 700 ms and 1200 ms) during which 64-channel EEG data were recorded. Behavioral reaction times (RTs) were longer in response to valid-cued trials than to invalid-cued ones, suggesting an intact IOR in SCZ. However, reduced N1 amplitude elicited by valid-cued trials suggested a stronger inhibition of attention from being oriented to a previously cued location, and therefore a relative inhibition of perceptual processing at that location in SCZ. These results indicate that altered N1 activity is associated with the preservation of IOR in SCZ and could be a sensitive marker to track the IOR effect.
Decreased cortical thickness in drug naÃ¯ve first episode schizophrenia: in relation to serum levels of BDNF. - Journal of psychiatric research
This study was to examine cortical thickness in drug naÃ¯ve, first episode schizophrenia patients, and to explore its relationship with serum levels of brain-derived neurotrophic factor (BDNF). Forty-five drug naive schizophrenia patients and 28 healthy controls were enrolled in the study. Freesurfer was used to parcellate cortical regions, and vertex-wise group analysis was used for whole brain cortical thickness. The clusters for the brain regions that demonstrated group differences were extracted, and the mean values of thickness were calculated. Serum levels of BDNF were measured using enzyme-linked immunosorbent assay (ELISA). After controlling for age and gender, significantly thinner cortical thickness was found in left insula and superior temporal gyrus in the patient group compared with the healthy control group (HC group) (p's < 0.001). Lower serum levels of BDNF were also found in the patient group compared with the HC group (p = 0.001). Correlation analysis showed a significant positive relationship between thickness of left insula and serum levels of BDNF within the HC group (r = 0.396, p = 0.037) but there was no such relationship within the patient group (r = 0.035, p = 0.819). Cortical thinning is present in drug naÃ¯ve, first episode schizophrenia patients, indicating neurodevelopmental abnormalities at the onset of schizophrenia. Left insula might be an imaging biomarker in detecting the impaired protective role of neurotrophic factor for the brain development in schizophrenia.Copyright Â© 2014 Elsevier Ltd. All rights reserved.
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. - Behavioral and brain functions : BBF
Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear.Two hundred and fifty drug naÃ¯ve, Chinese Han patients with first-episode schizophrenia were enrolled in the study, and genotyped for four single nucleotide polymorphisms (SNPs rs9939609, rs8050136, rs1421085 and rs9930506) by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequencing. Body weight and body mass index (BMI) were measured at baseline and six months after risperidone treatment.At baseline, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609; body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p's < 0.05). After 6 months of risperidone treatment, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609 (p's <0.01); body weight and BMI of CC homozygotes were lower than those of A allele carriers in rs8050136 (p's < 0.05); body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p's < 0.05). After controlling for age, gender, age of illness onset, disease duration, weight at baseline and education, weight gain of TT homozygotes at 6 months remained to be lower than those of A allele carriers in rs9939609 (p < 0.01); weight gain of CC homozygotes at 6 months was lower than those of A allele carriers in rs8050136 (p = 0.01). Stepwise multiple regression analysis suggested that, among 4 SNPs, rs9939609 was the strongest predictor of weight gain after 6 months of risperidone treatment (p = 0.001).The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia.
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. - Schizophrenia research
The aim of this study was to investigate the role of pravastatin, as an adjunctive therapy, on inflammatory markers, lipid and glucose metabolism, psychopathology, and cognition in subjects with schizophrenia and schizoaffective disorder.Schizophrenia or schizoaffective subjects (N=60) were randomized to receive either a 12-week supply of pravastatin 40 mg/day or placebo treatment. Anthropometric measures, lipids and glucose metabolism, inflammatory markers, psychopathology and cognitive performance were assessed at baseline, 6 weeks and 12 weeks.Pravastatin use was associated with a significant decrease in total cholesterol, low density lipoprotein (LDL) cholesterol and LDL particle number levels, but was not associated with any significant changes in cognition or psychopathology in the participants, except a significant decrease in the Positive and Negative Syndrome Scale (PANSS) positive symptom score from baseline to week 6. However, this decrease failed to remain significant at 12 weeks. Interestingly, triglycerides, LDL-cholesterol, total cholesterol, LDL particle number, small LDL particle number, large very low density lipoprotein (VLDL) particle number and C-reactive protein (CRP) followed a similar pattern at 6 and 12 weeks as psychopathology.These results suggest that a randomized trial with a larger sample size and a higher dosage of pravastatin would be helpful in further evaluating the anti-inflammatory properties of pravastatin, its association with improvements in cognitive symptoms, and its potential to reduce positive and negative symptoms associated with schizophrenia or schizoaffective disorders.Copyright Â© 2014 Elsevier B.V. All rights reserved.
Schizophrenia and the gut-brain axis. - Progress in neuro-psychopharmacology & biological psychiatry
Several risk factors for the development of schizophrenia can be linked through a common pathway in the intestinal tract. It is now increasingly recognized that bidirectional communication exists between the brain and the gut that uses neural, hormonal, and immunological routes. An increased incidence of gastrointestinal (GI) barrier dysfunction, food antigen sensitivity, inflammation, and the metabolic syndrome is seen in schizophrenia. These findings may be influenced by the composition of the gut microbiota. A significant subgroup of patients may benefit from the initiation of a gluten and casein-free diet. Antimicrobials and probiotics have therapeutic potential for reducing the metabolic dysfunction and immune dysregulation seen in patients with schizophrenia.Copyright Â© 2014 Elsevier Inc. All rights reserved.
Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: a study of drug naive, first-episode schizophrenia patients and unaffected siblings. - Schizophrenia research
Studies have shown that patients with schizophrenia and their siblings share decreased gray matter (GM) volumes in certain brain regions, which may represent candidate endophenotypes of schizophrenia. However, the specificity and utility of these possible endophenotypes in relation to schizophrenia remain unclear.Twenty drug-naive, first-episode schizophrenia patients and 20 first-degree unaffected siblings from the same families as the patients (USS group), a separate group of 25 first-degree unaffected siblings of schizophrenia patients from other families (USO group), and 43 healthy controls were recruited. Voxel-based morphometry (VBM) was used to analyze structural imaging data.The VBM analysis showed a significant difference in GM volume between the combined sibling group and the control group in the left middle temporal gyrus (MTG). Group comparison showed that the patients, the USS, and the USO had significantly decreased GM volume of the left MTG compared with the controls; such a difference did not exist among the patients and the two sibling groups. A receiver operating characteristic curve (ROC curve) analysis showed good predictive value of the mean cluster volume in the left MTG to distinguish patients, USS, and USO from healthy controls. There were no significant correlations between the mean cluster volume in the left MTG and clinical variables in the patients.The GM volume decrease of the left MTG may be utilized as a candidate biomarker for schizophrenia. The novel design of including a USO group in our study enhances both the specificity and the heritability of the biomarker identified.Copyright Â© 2014 Elsevier B.V. All rights reserved.
Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naÃ¯ve, first episode schizophrenia. - Schizophrenia research
The present study was to examine serum levels of brain-derived neurotrophic factor (BDNF), folate, homocysteine (Hcy), and their relationships with hippocampal volume and psychopathology in drug naÃ¯ve, first episode schizophrenia.Drug naÃ¯ve, first episode schizophrenia patients and healthy controls were enrolled in the study. Serum levels of BDNF, folate and Hcy were measured using enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence immunoassay (ECLIA), and enzymatic cycling method respectively. Hippocampus was parcellated and bilateral hippocampal volumes were measured using FreeSurfer.Forty-six patients with drug naÃ¯ve, first episode schizophrenia (SZ group) and 30 healthy controls (control group) were enrolled. The SZ group had significantly lower serum levels of BDNF and folate, and significantly higher serum levels of Hcy compared with the control group (p=0.013, p<0.001, p=0.003 respectively). There were no significant differences in hippocampal volumes between the two groups (ps>0.2). Within the SZ group, there were significant positive relationships between serum levels of BDNF and both left and right hippocampal volumes (r=0.327, p=0.026; r=0.338, p=0.022 respectively). In contrast, such relationships did not exist in the control group. Within the SZ group, there were significant negative relationships between serum levels of folate and PANSS-total scores and PANSS-negative symptom scores (r=0.319, p=0.031; r=0.321, p=0.030 respectively); and there was a positive relationship between serum levels of Hcy and PANSS-total scores (r=0.312, p=0.035). Controlling for potential confounding variables resulted in similar findings.Drug naÃ¯ve, first episode schizophrenia presents decreased serum levels of BDNF, folate and increased serum levels of Hcy, which may play an important role in the neurodevelopmental process and clinical manifestation of schizophrenia.Copyright Â© 2014. Published by Elsevier B.V.
Phenotypic characteristics in metabolically healthy but obese patients with schizophrenia. - Psychiatry research
The purpose of this study was to characterize phenotypic characteristics of metabolically healthy but obese individuals with schizophrenia. Participants were non-diabetic outpatients 19 to 75 years old diagnosed with schizophrenia or schizoaffective disorder. Obese patients (body mass index (BMI)>30 kg/m(2)) were included in the present analysis. Patients were further defined as metabolically healthy but obese or obese individuals with metabolic abnormalities based on a cut-off value of 2.5 using the homeostasis model assessment of insulin resistance (HOMA-IR). Fasting blood samples were collected to determine levels of various metabolic parameters. Lipoprotein subclass concentrations and sizes were analyzed using nuclear magnetic resonance (NMR) spectroscopy. Fourteen metabolically healthy but obese patients and 62 obese patients with metabolic abnormalities were identified from 206 patients with schizophrenia. After controlling for age, there were no significant differences between the two groups on anthropometric measures. However, the metabolically healthy but obese group had significantly lower levels of large VLDL particle, significantly higher levels of intermediate VLDL particle, and significantly smaller mean particle size in VLDL compared with the obese group with metabolic abnormalities (metabolically obese). A metabolically healthy but obese phenotype characterized by high levels of intermediate VLDL particle and low levels of large VLDL particle exists in obese, non-diabetic patients with schizophrenia.Copyright Â© 2014 Elsevier Ireland Ltd. All rights reserved.
What can the medical education do for eliminating stigma and discrimination associated with mental illness among future doctors? effect of clerkship training on chinese students' attitudes. - International journal of psychiatry in medicine
The study was to examine the changes in attitudes towards psychiatry and mental illness among Chinese medical students during their psychiatry clerkship training.The Attitudes Towards Mental Illness (AMI) and the Attitudes Towards Psychiatry-30 (ATP-30) questionnaires were administered to 325 fourth-year Chinese medical students before and after they completed an 8-week psychiatry clerkship training.After the clerkship training, there was a significant improvement in attitudes towards psychiatry and mental health as reflected by the total scores on ATP-30 (103.4 Â± 8.6 versus 111.8 Â± 9.6, p < 0.001) and AMI (58.9 Â± 6.3 versus 64.1 Â± 6.6, p < 0.001). The proportions of students who showed positive attitudes to psychiatry and mental illness were significantly increased on most of the items on ATP-30 and AMI after rotation (p's = 0.027). Although there was a significant change after training, the percentage of the students who would consider psychiatry as their future medical specialty was still on a low level (6.5% versus 11.4%, before versus after rotation, p = 0.028).The results of our study suggested that psychiatry clerkship training may improve medical students' attitudes towards psychiatry and mental illness, but its influence on medical students' consideration to choose psychiatry as a future medical career is limited. The students who did not consider psychiatry as a future career held less positive attitudes to psychiatrists, psychiatric patients and the treatment.
Map & Directions
25 Staniford St Erich Lindemann Mtl Hlth Ctr Boston, MA 02114
Massachusetts General Hospital 55 Fruit Street
55 Fruit Street Massachusetts General Hospital
Massachusetts General Hospital 55 Fruit Street
Massachusetts General Hospital 55 Fruit Street
15 Parkman St Wac 8-835, Massachusetts General Hospital
Massachusetts General Hospital 55 Fruit Street
Massachusetts General Hospital 55 Fruit St.